MedTrace Logo

Lorcaserin for Preventing Weight Gain Among Smokers

NCT02393547 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2017-06-06

Study results available
· View outcomes & findings →

Summary

This will be an open label clinical trial with all subjects receiving both lorcaserin and varenicline with a primary aim of reducing post cessation weight gain.

Conditions

  • Tobacco Use Disorder
  • Weight Gain

Interventions

DRUG

Varenicline

All subjects receive Varenicline

DRUG

Lorcaserin

All subjects receive Lorcaserin

Sponsors & Collaborators

Principal Investigators

  • Ryan Hurt, MD, PhD · Mayo Clinic

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02393547 on ClinicalTrials.gov